Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Theravance Biopharma stock

Learn how to easily invest in Theravance Biopharma stock.

Theravance Biopharma is a biotechnology business based in the US. Theravance Biopharma shares (TBPH) are listed on the NASDAQ and all prices are listed in US Dollars. Theravance Biopharma employs 158 staff and has a trailing 12-month revenue of around $51.6 million.

How to buy Theravance Biopharma stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – TBPH. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience

Robinhood


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance

Promoted

tastyworks


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Theravance Biopharma stock price (NASDAQ: TBPH)

Use our graph to track the performance of TBPH stocks over time.

Theravance Biopharma shares at a glance

Information last updated 2023-01-25.
Latest market close$10.67
52-week range$7.53 - $11.83
50-day moving average $10.94
200-day moving average $9.80
Wall St. target price$12.56
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.02

Buy Theravance Biopharma stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Theravance Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Theravance Biopharma price performance over time

Historical closes compared with the close of $10.67 from 2023-01-26

1 week (2023-01-20) -3.83%
1 month (2022-12-28) -4.48%
3 months (2022-10-28) 6.81%
6 months (2022-07-28) 20.43%
1 year (2022-01-27) 27.94%
2 years (2021-01-28) -41.73%
3 years (2020-01-28) 27.2
5 years (2018-01-26) 28.98

Theravance Biopharma financials

Revenue TTM $51.6 million
Gross profit TTM $-138,346,000
Return on assets TTM -10.81%
Return on equity TTM -90.12%
Profit margin 1646.81%
Book value $7.13
Market capitalisation $740.4 million

TTM: trailing 12 months

Theravance Biopharma share dividends

We're not expecting Theravance Biopharma to pay a dividend over the next 12 months.

Theravance Biopharma share price volatility

Over the last 12 months, Theravance Biopharma's shares have ranged in value from as little as $7.53 up to $11.83. A popular way to gauge a stock's volatility is its "beta".

TBPH.US volatility(beta: 0.53)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Theravance Biopharma's is 0.5309. This would suggest that Theravance Biopharma's shares are less volatile than average (for this exchange).

Theravance Biopharma overview

Theravance Biopharma, Inc. , a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc.

Frequently asked questions

What percentage of Theravance Biopharma is owned by insiders or institutions?
Currently 11.196% of Theravance Biopharma shares are held by insiders and 98.473% by institutions.
How many people work for Theravance Biopharma?
Latest data suggests 158 work at Theravance Biopharma.
When does the fiscal year end for Theravance Biopharma?
Theravance Biopharma's fiscal year ends in December.
Where is Theravance Biopharma based?
Theravance Biopharma's address is: Ugland House, George Town, Cayman Islands, KY1-1104
What is Theravance Biopharma's ISIN number?
Theravance Biopharma's international securities identification number is: KYG8807B1068
What is Theravance Biopharma's CUSIP number?
Theravance Biopharma's Committee on Uniform Securities Identification Procedures number is: G8807B106

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site